Invivyd, Inc.

NasdaqGM IVVD

Invivyd, Inc. Price to Sales Ratio (P/S) on February 06, 2025: 16.24

Invivyd, Inc. Price to Sales Ratio (P/S) is 16.24 on February 06, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Invivyd, Inc. 52-week high Price to Sales Ratio (P/S) is 17.30 on February 05, 2025, which is 6.57% above the current Price to Sales Ratio (P/S).
Invivyd, Inc. 52-week low Price to Sales Ratio (P/S) is 2.93 on January 31, 2025, which is -81.93% below the current Price to Sales Ratio (P/S).
Invivyd, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 6.13.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: IVVD

Invivyd, Inc.

CEO	Dr. Robert D. Allen Ph.D.
IPO Date	Aug. 6, 2021
Location	United States
Headquarters	1601 Trapelo Road
Employees	94
Sector	Healthcare
Industries Vaccines Biotechnology Clinical Trials Pharmaceuticals

Description

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Key trends

Past 5 years